These Analysts Revise Their Forecasts On Hims & Hers Health After Q3 Results

Hims & Hers Health Inc. (NYSE:HIMS) on Monday posted downbeat third-quarter fiscal 2026 results. 

Hims & Hers Health reported quarterly losses of 14 cents per share, which missed the analyst estimate of earnings of eight cents, per Benzinga Pro data. Quarterly revenue of $890.37 million missed the Street estimate of $892.89 million, but was up from $598.98 million in the same period last year.

"In health care, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them," said Andrew Dudum, co-founder and CEO.

Hims & Hers Health expects fourth-quarter revenue in a range of $875 million to $895 million, versus the $953.45 million analyst estimate. The company narrowed its fiscal 2026 revenue outlook to between $3.13 billion and $3.15 billion, versus the $3.21 billion estimate.

Hims & Hers Health shares fell 13.3% to trade at $19.86 on Tuesday.

These analysts made changes to their price targets on Hims & Hers Health following earnings announcement.

• Needham analyst Ryan MacDonald maintained the stock with a Buy and lowered the price target from $42 to $32.
• Evercore ISI Group analyst Mark Mahaney maintained the stock with an In-Line rating and raised the price target from $24 to $27.

Considering buying HIMS stock? Here’s what analysts think:

Photo via Shutterstock